Genetic Predictors of Adverse Radiotherapy Effects: The Gene-PARE project
Journal Article
·
· International Journal of Radiation Oncology, Biology and Physics
- Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY (United States)
- Department of Radiation Oncology, New York University School of Medicine, New York, NY (United States)
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (United States)
- Department of Oncology, Rambam Medical Center, Haifa (Israel)
- Department of Radiation Oncology, CRLC Val d'Aurelle, Montpellier (France)
- Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne (Switzerland)
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus (Denmark)
- Department of Urology, Bronx VA Medical Center, Bronx, NY (United States)
- Department of Radiation Oncology, Bronx VA Medical Center, Bronx, NY (United States)
Purpose: The development of adverse effects resulting from the radiotherapy of cancer limits the use of this treatment modality. The validation of a test capable of predicting which patients would be most likely to develop adverse responses to radiation treatment, based on the possession of specific genetic variants, would therefore be of value. The purpose of the Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE) project is to help achieve this goal. Methods and Materials: A continuously expanding biorepository has been created consisting of frozen lymphocytes and DNA isolated from patients treated with radiotherapy. In conjunction with this biorepository, a database is maintained with detailed clinical information pertaining to diagnosis, treatment, and outcome. The DNA samples are screened using denaturing high performance liquid chromatography (DHPLC) and the Surveyor nuclease assay for variants in ATM, TGFB1, XRCC1, XRCC3, SOD2, and hHR21. It is anticipated that additional genes that control the biologic response to radiation will be screened in future work. Results: Evidence has been obtained that possession of variants in genes, the products of which play a role in radiation response, is predictive for the development of adverse effects after radiotherapy. Conclusions: It is anticipated that the Gene-PARE project will yield information that will allow radiation oncologists to use genetic data to optimize treatment on an individual basis.
- OSTI ID:
- 20842891
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 3 Vol. 65; ISSN IOBPD3; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Association Between Genetic Polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT Genes and Radiosensitivity in Breast Cancer Patients
Possession of ATM Sequence Variants as Predictor for Late Normal Tissue Responses in Breast Cancer Patients Treated With Radiotherapy
TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy
Journal Article
·
Thu Sep 01 00:00:00 EDT 2011
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21587705
Possession of ATM Sequence Variants as Predictor for Late Normal Tissue Responses in Breast Cancer Patients Treated With Radiotherapy
Journal Article
·
Thu Nov 01 00:00:00 EDT 2007
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21039568
TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy
Journal Article
·
Fri Feb 29 23:00:00 EST 2008
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21039789